tradingkey.logo

Veracyte Inc

VCYT
查看详细走势图
42.455USD
-0.315-0.74%
交易中 美东报价延迟15分钟
3.36B总市值
109.66市盈率 TTM

Veracyte Inc

42.455
-0.315-0.74%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.74%

5天

+0.99%

1月

-14.02%

6月

+60.51%

今年开始到现在

+7.21%

1年

+3.10%

查看详细走势图

TradingKey Veracyte Inc股票评分

单位: USD 更新时间: 2025-12-24

操作建议

Veracyte Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名30/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价48.36。中期看,股价处于上升通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Veracyte Inc评分

相关信息

行业排名
30 / 404
全市场排名
102 / 4562
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 13 位分析师
买入
评级
48.364
目标均价
+9.03%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Veracyte Inc亮点

亮点风险
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
业绩高增长
公司营业收入稳步增长,连续3年增长50.32%
业绩转盈
公司业绩转盈,最新年度盈利美元
估值高估
公司最新PE估值110.47,处于3年历史高位
机构减仓
最新机构持股87.37M股,环比减少1.63%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值414.70K

Veracyte Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Veracyte Inc简介

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
公司代码VCYT
公司Veracyte Inc
CEOStapley (Marc A)
网址https://www.veracyte.com/

常见问题

Veracyte Inc(VCYT)的当前股价是多少?

Veracyte Inc(VCYT)的当前股价是 42.455。

Veracyte Inc的股票代码是什么?

Veracyte Inc的股票代码是VCYT。

Veracyte Inc股票的52周最高点是多少?

Veracyte Inc股票的52周最高点是50.710。

Veracyte Inc股票的52周最低点是多少?

Veracyte Inc股票的52周最低点是22.610。

Veracyte Inc的市值是多少?

Veracyte Inc的市值是3.36B。

Veracyte Inc的净利润是多少?

Veracyte Inc的净利润为24.14M。

现在Veracyte Inc(VCYT)的股票是买入、持有还是卖出?

根据分析师评级,Veracyte Inc(VCYT)的总体评级为买入,目标价格为48.364。

Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是多少

Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是0.387。
KeyAI